Erlotinib hydrochloride

Research use only, not for human use.

Erlotinib (CP-358774;OSI-774;NSC 718781) is a potent, selective inhibitor of EGFR with IC50 of 2 nM.

Erlotinib (CP-358774;OSI-774;NSC 718781) is a potent, selective inhibitor of EGFR with IC50 of 2 nM; reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM; inhibits the proliferation of DiFi human colon tumor cells at submicromolar concentrations in cell culture and blocks cell cycle progression at the G1 phase; 100mg/kg completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice; orally active.Lung Cancer Approved

CP-358774;OSI-774;NSC 718781

Angiogenesis

EGFR

EGFR/HER1

Cancer

Lung Cancer

183319-69-9

429.90

C22H24ClN3O4

>98% (HPLC)

DMSO: ≥ 4.3 mg/mL; DMSO: 6.2 mg/mL (Need ultrasonic and warming)

Cl.COCCOC1=C(OCCOC)C=C2C(NC3=CC=CC(=C3)C#C)=NC=NC2=C1

4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years